EGFR and prostate carcinoma: Conversely, a transient upregulation of EGFR was shown in the prostate carcinoma cell line DU-145 after treatment with the HDACi SN30028, which inhibits not only class I HDACs, but also the class IIb representative HDAC6 [39].